Menu
Fechar
HRS4R
Vull donar
Firma
ÈLIA SAIS-GIRONA
Posició
Investigador/a Pre-doctoral – R1
Investigadors/es Pre-doctorals – R1
Projectes
Publicacions

Projectes

Estudio descriptivo y efecto del ritmo circadiano en el tratamiento con quimio-inmunoterapia neoadyuvante del cáncer del pulmón de célula no pequeña en estadios precoces. Un estudio multicéntrico con resultados de Real World Data (RWD)

Codi oficial: 2024_GECP_CMF Data inici: 01/12/2024 Data fi: 30/11/2026 Investigador/a principal: CLAUDIA MONTAÑES FERRER Organisme finançador: GRUPO ESPAÑOL DE CANCER DE PULMON

Publicacions

Teixidor-Vilà E, Trallero J, Puigdemont M, Vidal-Vila A, Hernandez-Martínez A, Sais E, Sabaté-Ortega J, Verdura S, Menendez JA, Bosch-Barrera J, Sanvisens A, Marcos-Gragera R

Lung cancer survival trends and prognostic factors: A 26-year population-based study in Girona Province, Spain.

LUNG CANCER, 2024, 197, 107995-107995 dx.doi.org/10.1016/j.lungcan.2024.107995
Teixidor E, Sais E, Vásquez CA, Carbajal W, Hernández A, Sánchez G, Izquierdo A, Verdura S, Menéndez JA, Bosch-Barrera J

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Oncotarget, 2023, 14, 668-668 dx.doi.org/10.18632/oncotarget.28471
Bosch-Barrera, J, Teixidor, E, Sanvisens, A, Puigdemont, M, Trallero, J, Vila, AV, Osca, G, Roberte, MV, Priego, N, Sais, E, Martínez, AH, Ortega, JS, Cuyàs, E, Verdura, S, Puig, J, Pineda, V, Martí-Navas, M, Calvo, A, Menendez, JA, Marcos-Gragera, R, Valiente, M

Using Silibinin to Target STAT3-Positive Reactive Astrocytes for the Treatment of NSCLC Brain Metastases

JOURNAL OF THORACIC ONCOLOGY, 2023, 18, 426-427
Monteiro C, Miarka L, Perea-García M, Priego N, García-Gómez P, Álvaro-Espinosa L, de Pablos-Aragoneses A, Yebra N, Retana D, Baena P, Fustero-Torre C, Graña-Castro O, Troulé K, Caleiras E, Tezanos P, Muela P, Cintado E, Trejo JL, Sepúlveda JM, González-León P, Jiménez-Roldán L, Moreno LM, Esteban O, Pérez-Núñez Á, Hernández-Lain A, Mazarico Gallego J, Ferrer I, Suárez R, Garrido-Martín EM, Paz-Ares L, Dalmasso C, Cohen-Jonathan Moyal E, Siegfried A, Hegarty A, Keelan S, Varešlija D, Young LS, Mohme M, Goy Y, Wikman H, Fernández-Alén J, Blasco G, Alcázar L, Cabañuz C, Grivennikov SI, Ianus A, Shemesh N, Faria CC, Lee R, Lorigan P, Le Rhun E, Weller M, Soffietti R, Bertero L, Ricardi U, Bosch-Barrera J, Sais E, Teixidor E, Hernández-Martínez A, Calvo A, Aristu J, Martin SM, Gonzalez A, Adler O, Erez N, RENACER, Valiente M

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

NATURE MEDICINE, 2022, 28, 752-765 dx.doi.org/10.1038/s41591-022-01749-8
Bosch-Barrera J, Verdura S, Ruffinelli JC, Carcereny E, Sais E, Cuyàs E, Palmero R, Lopez-Bonet E, Hernández-Martínez A, Oliveras G, Buxó M, Izquierdo A, Morán T, Nadal E, Menendez JA

Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer

Cancers, 2021, 13 dx.doi.org/10.3390/cancers13164168
Bosch-Barrera J, Oliva E, Sais E, Vásquez CA, Roselló A, Menéndez JA

Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer

ANTI-CANCER DRUGS, 2019, 30, 1067-1070 dx.doi.org/10.1097/CAD.0000000000000837
Morán T, Felip E, Bosch-Barrera J, de Aguirre I, Ramirez JL, Mesia C, Carcereny E, Roa D, Sais E, García Y, Blanco R, Sanchez S, Villacorta CR, Queralt C, Velarde JM, Rosell R

Correction: Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.

Oncotarget, 2019, 10, 2576-2576 dx.doi.org/10.18632/oncotarget.26855
Teixidor E, Sais E, Vásquez CA, Carbajal W, Hernández A, Sánchez G, Izquierdo A, Verdura S, Menéndez JA, Bosch-Barrera J

Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Oncotarget, 2018, 9, 33043-33049 dx.doi.org/10.18632/oncotarget.25984
Morán T, Felip E, Bosch-Barrera J, de Aguirre I, Ramirez JL, Mesia C, Carcereny E, Roa D, Sais E, García Y, Blanco R, Sanchez S, Villacorta CR, Queralt C, Velarde JM, Rosell R

Monitoring EGFR -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.

Oncotarget, 2018, 9, 27074-27086 dx.doi.org/10.18632/oncotarget.25478
López Brunsó M, Toro Blanch C, Sais Girona E, Roa García D, Hernández Martínez A, Izquierdo Font A, Guerra Prió S, Mas Pueyo HG, Bosch-Barrera J

Probable drug-drug interaction between erlotinib and amiodarone causes severe neurotoxicity in a patient with advanced lung cancer

ANTI-CANCER DRUGS, 2018, 29, 380-383 dx.doi.org/10.1097/CAD.0000000000000600

Formulari de contacte

Coneix l’IDIBGI!

 menu